Tailored cardiac organoids for robust preclinical decision-making

How can the efficacy and cardiac risks of new therapies be investigated at an early stage using human-relevant models?

Developing new therapies for heart disease requires model systems that replicate the complexity of human cardiac tissue as closely as possible. Conventional cell cultures do not adequately capture many disease-relevant cell–cell interactions, while animal models reflect human physiology only to a limited extent. Our modular human cardiac organoids provide a human-relevant platform for investigating disease mechanisms, evaluating drug efficacy and identifying cardiac safety risks at an early stage.

By selectively combining different cell types with patient-specific or genetically defined cells, we develop tailored models precisely aligned with your research and development questions. Based on established multicellular cardiac organoid models, these systems can be used to investigate therapeutic effects, genetic diseases, inflammatory processes and cardiac safety aspects, among other applications.

How we can support you!

From 2D models to multicellular cardiac organoids: Together, we select the right cardiac model system to investigate disease mechanisms, therapeutic effects and safety risks.

Precision modeling of cardiac diseases

 

We develop tailored cardiac organoids with a defined cellular composition to investigate genetic heart diseases and disease-relevant mechanisms.
 

Application examples

  • Hypertrophic cardiomyopathy (HCM)
  • Genetic cardiomyopathies
  • Patient-specific disease models
  • Target validation for new therapeutic approaches

Functional efficacy testing

 

Quantitative functional readouts enable the evaluation of therapeutic effects directly in the organoid model and support the development of innovative therapies..
 

Suitable for

  • Small Molecules
  • RNA therapeutics
  • Gene therapies
  • Biologics
  • Viral vector systems

Cardiac safety assessment

 

Human cardiac organoids support the early identification of potential cardiac safety risks in a human-relevant model system.
 

Potential endpoints

  • Contraction amplitude
  • Contraction duration
  • Relaxation kinetics
  • Morphology
  • Molecular biomarkers

Immunocompetent cardiac organoids

 

Integrating macrophages and other immune cells enables the investigation of inflammatory processes and immune–heart interactions.
 

Applications

  • Cardiac inflammation
  • Immune-mediated cardiotoxicity
  • Immunomodulatory therapies
  • Inflammation-driven diseases

Benefits for you: Why human cardiac organoids?

Person zeigt auf die vergrößerte Darstellung eines humanen Herzorganoids auf einem Bildschirm.
© Fraunhofer ITEM

Human cardiac organoids enable the investigation of complex disease mechanisms in a human-relevant microenvironment. Their controllable cellular composition combines disease modeling, efficacy testing and safety assessment in a flexible platform for preclinical research and drug development.

Your benefits at a glance

  • Human-relevant modeling of complex heart diseases
  • Defined and adaptable cellular composition
  • Investigation of genetic, inflammatory and treatment-related effects
  • Quantifiable functional endpoints
  • Suitable for modern treatment modalities such as RNA and gene therapies
  • Early evaluation of efficacy and safety
  • Adaptable to specific research and development questions

Looking to investigate a cardiac research question in a human-relevant model?

Talk to us about suitable cardiac organoid models, functional endpoints and tailored study designs for your research and development objectives.

Christian Bär

Contact Press / Media

Prof. Dr. Christian Bär

Manager of the Working Group on RNA Technology and Regenerative Strategies

Phone +49 511 5350-120

Sebastian Konzok

Contact Press / Media

Dr. Sebastian Konzok

Business Development Manager Preclinical Pharmacology and Toxicology

Phone +49 160 927 200 20

Application Examples

Use Case 01

Evaluating gene therapies for hypertrophic cardiomyopathy

Research question
Can an RNA or gene therapy improve functional impairments in hypertrophic cardiomyopathy?

Our approach
We assessed the functional effects of AAV-mediated circZFPM2 overexpression in a controlled disease model using genetically defined human cardiac organoids.

Result
The treatment measurably improved contraction and relaxation kinetics and confirmed the potential of cardiac organoids for preclinical RNA and gene therapy testing.

Use Case 02

Demonstrating the functional efficacy of new HCM therapies

Research question
How can the effects of new HCM drugs be assessed in a human-relevant model?

Our approach
Genetically defined cardiac organoids were used to investigate the effects of mavacamten on contraction amplitude and relaxation kinetics.

Result
The organoids showed reproducible responses and enabled therapeutic effects to be quantified – providing a basis for the preclinical evaluation of new drug candidates.

Answers to frequently asked questions about human cardiac organoids

Relevant Publications

Kiselev E, Agyapong W, Jürgens B, Mohr E, Chatterjee S, Hunkler HJ, Salman J, Cipriano G, Bentele M, Liu J, Specht J, Menge KS, Waleczek FJG, Haas JA, Derda AA, Sonnenschein K, Gietz A, Neumüller S, Pfanne A, Beetz O, Pflaum M, Wiegmann B, Psaras Y, Toepfer C, Zweigerdt R, Radocaj A, Kraft T, Zeug A, Ponimaskin E, Korte W, Horke A, Ruhparwar A, Fuchs M, Xiao K, Bär C, Weber N, Thum T. Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy. Br J Pharmacol. 2026 Mar;183(5):1122-1139. doi: 10.1111/bph.70247. Epub 2025 Nov 10. PMID: 41215595.

Durán V, Nikolouli E, Chatterjee S, Costa B, Pavlou A, Ziegler A, Becker J, Baumann K, Bruhn M, Haake K, Hashtchin AR, Gensch I, Korte A, Behrens YL, Zhang SY, Casanova JL, Bär C, Lachmann N, Thum T, Kalinke U. Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages. J Clin Immunol. 2025 Oct 21;45(1):149. doi: 10.1007/s10875-025-01943-6. PMID: 41117873; PMCID: PMC12540622.

Costa A, Boese A, Mohr E, Borisch C, Hunkler HJ, Hoepfner J, Chatterjee S, Thum T, Bär C. Generation of a human induced pluripotent stem cell reporter line to investigate cell division and proliferation. Stem Cell Res. 2025 Sep;87:103776. doi: 10.1016/j.scr.2025.103776. Epub 2025 Jul 16. PMID: 40694867.

Juchem M, Lehmann N, Behrens YL, Bär C, Thum T, Hoepfner J. CRISPR/Cas9-based GLA knockout to generate the female Fabry disease human induced pluripotent stem cell line MHHi001-A-15. Stem Cell Res. 2024 Sep;79:103478. doi: 10.1016/j.scr.2024.103478. Epub 2024 Jun 20. PMID: 38905814.

Neufeldt D, Schmidt A, Mohr E, Lu D, Chatterjee S, Fuchs M, Xiao K, Pan W, Cushman S, Jahn C, Juchem M, Hunkler HJ, Cipriano G, Jürgens B, Schmidt K, Groß S, Jung M, Hoepfner J, Weber N, Foo R, Pich A, Zweigerdt R, Kraft T, Thum T, Bär C. Circular RNA circZFPM2 regulates cardiomyocyte hypertrophy and survival. Basic Res Cardiol. 2024 Aug;119(4):613-632. doi: 10.1007/s00395-024-01048-y. Epub 2024 Apr 19. PMID: 38639887; PMCID: PMC11319402.

Jahn C, Juchem M, Sonnenschein K, Gietz A, Buchegger T, Lachmann N, Göhring G, Behrens YL, Bär C, Thum T, Hoepfner J. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation. Stem Cell Res. 2024 Jun;77:103404. doi: 10.1016/j.scr.2024.103404. Epub 2024 Mar 24. PMID: 38552356.

Mohr E, Thum T, Bär C. Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models. Eur J Heart Fail. 2022 Oct;24(10):1778-1791. doi: 10.1002/ejhf.2631. Epub 2022 Aug 4. PMID: 35867781.